Literature DB >> 20623257

[Alpha1-antitrypsin deficiency in Austria: analysis of the Austrian Alpha1-international-registry database].

Florian Huber1, Karin Schmid-Scherzer, Felix Wantke, Sophie Frantal, Meinhard Kneussl.   

Abstract

OBJECTIVE: Alpha1-antitrypsin deficiency is a rare hereditary disorder. Deficient patients are at a higher risk to develop lung emphysema at an early age. The alpha1-antitrypsin registry was founded on 1996 to get new insights into the pathogenesis of the disease and to develop new therapeutic strategies. In this study the epidemiological and clinical findings of the Austrian alpha1-antitrypsin deficient patients are presented.
MATERIAL AND METHODS: A total of 139 patients with severe alpha1-antitrypsin deficiency, identified by phenol- and genotyping, were evaluated retrospectively by their physicians with the help of a questionnaire.
RESULTS: Most patients were smokers or ex-smokers (71.9%) who developed symptoms in their fourth decade. The mean duration between the onset of symptoms and the final diagnosis was 6.5 years. About 25% of the evaluated patients were unable to practice their profession because of their illness.
CONCLUSION: Alpha1-antitrypsin deficiency is a rare condition with delayed diagnosis. Because of the benefit of an early diagnosis further effort should be put towards early detection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20623257     DOI: 10.1007/s00508-010-1399-9

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  36 in total

1.  A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.

Authors:  A Dirksen; J H Dijkman; F Madsen; B Stoel; D C Hutchison; C S Ulrik; L T Skovgaard; A Kok-Jensen; A Rudolphus; N Seersholm; H A Vrooman; J H Reiber; N C Hansen; T Heckscher; K Viskum; J Stolk
Journal:  Am J Respir Crit Care Med       Date:  1999-11       Impact factor: 21.405

2.  Alpha-1 antitrypsin deficiency: an under-recognized but important issue for respiratory therapists.

Authors:  James K Stoller
Journal:  Respir Care       Date:  2003-11       Impact factor: 2.258

3.  Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group.

Authors:  N G McElvaney; J K Stoller; A S Buist; U B Prakash; M L Brantly; M D Schluchter; R D Crystal
Journal:  Chest       Date:  1997-02       Impact factor: 9.410

Review 4.  Serine proteinase inhibitor therapy in alpha(1)-antitrypsin inhibitor deficiency and cystic fibrosis.

Authors:  G Döring
Journal:  Pediatr Pulmonol       Date:  1999-11

5.  Environmental correlates of impaired lung function in non-smokers with severe alpha 1-antitrypsin deficiency (PiZZ).

Authors:  E Piitulainen; G Tornling; S Eriksson
Journal:  Thorax       Date:  1998-11       Impact factor: 9.139

Review 6.  Alpha-1-antitrypsin replacement therapy: current status.

Authors:  Hatem Abusriwil; Robert A Stockley
Journal:  Curr Opin Pulm Med       Date:  2006-03       Impact factor: 3.155

7.  Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem.

Authors:  James K Stoller; Robert A Sandhaus; Gerard Turino; Ryan Dickson; Keith Rodgers; Charlie Strange
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

Review 8.  Alpha1-antitrypsin deficiency. 1: epidemiology of alpha1-antitrypsin deficiency.

Authors:  M Luisetti; N Seersholm
Journal:  Thorax       Date:  2004-02       Impact factor: 9.139

9.  Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1998-07       Impact factor: 21.405

Review 10.  Augmentation therapy for alpha(1)-antitrypsin deficiency.

Authors:  Georges S Juvelekian; James K Stoller
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more
  2 in total

1.  [From "chronic bronchitis"to genetic emphysema].

Authors:  Friedrich Kummer
Journal:  Wien Klin Wochenschr       Date:  2010-10       Impact factor: 1.704

2.  Liver disease in adults with α1-antitrypsin deficiency.

Authors:  Mattias Mandorfer; Theresa Bucsics; Veronika Hutya; Karin Schmid-Scherzer; Benedikt Schaefer; Heinz Zoller; Arnulf Ferlitsch; Markus Peck-Radosavljevic; Michael Trauner; Peter Ferenci; Meinhard Kneussl; Thomas Reiberger
Journal:  United European Gastroenterol J       Date:  2018-02-28       Impact factor: 4.623

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.